Tuesday, April 29, 2025

ZyVersa Therapeutics Announces Published Data Showing Inflammasome ASC Inhibitor IC 100 Decreases Microglial Inflammasome Activation and Alpha-Synuclein That Contribute to Neurodegeneration in Parkins

29/04/2025

ZyVersa Therapeutics Announces Published Data Showing Inflammasome ASC Inhibitor IC 100 Decreases Microglial Inflammasome Activation and Alpha-Synuclein That Contribute to Neurodegeneration in Parkins#ZyVersa #Therapeutics #Announces #Published #Data #Showing #Inflammasome #ASC #Inhibitor #Decreases #Microglial #Inflammasome #Activation #AlphaSynuclein #Contribute #Neurodegeneration #Parkins

ZyVersa Therapeutics Announces Published Data Showing Inflammasome ASC Inhibitor IC 100 Decreases Microglial Inflammasome Activation and Alpha-Synuclein That Contribute to Neurodegeneration in Parkins

Carlisle Companies sets $1 dividend for June 2

Google Play sees 47% decline in apps since start of last year

Apple Earnings Preview: Beware The China Tariffs

SSAB AB (SSAAF) Q1 2025 Earnings Call Transcript

Amazon Prime Day to return in July despite threat of tariffs

Equities climb in choppy trade as earnings, data, tariffs gauged

Ecolab, Inc. (ECL) Q1 2025 Earnings Conference Call Transcript

Carlisle Companies sets $1 dividend for June 2

Google Play sees 47% decline in apps since start of last year

Carlisle Companies sets $1 dividend for June 2

Google Play sees 47% decline in apps since start of last year

Carlisle Companies sets $1 dividend for June 2

Google Play sees 47% decline in apps since start of last year